Coherus BioSciences IncNASDAQ:CHRS
- LAST PRICE1.2200
- TODAY'S CHANGE (%)-0.0400 (-3.1746%)
- Bid / Lots1.2400/ 2
- Ask / Lots1.2500/ 3
- Open / Previous Close1.2800 / 1.2600
- Day Range
- 52 Week Range
- Volume1,866,512
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CHRS |
|---|---|---|
| 09:32 ET | 99646 | 1.29 |
| 09:33 ET | 19101 | 1.295 |
| 09:35 ET | 8542 | 1.285 |
| 09:37 ET | 29144 | 1.3 |
| 09:39 ET | 46062 | 1.305 |
| 09:42 ET | 14304 | 1.295 |
| 09:44 ET | 19581 | 1.28 |
| 09:46 ET | 27062 | 1.26 |
| 09:48 ET | 12708 | 1.265 |
| 09:50 ET | 29810 | 1.2689 |
| 09:51 ET | 2000 | 1.265 |
| 09:53 ET | 33534 | 1.255 |
| 09:55 ET | 9881 | 1.265 |
| 09:57 ET | 4579 | 1.2699 |
| 10:00 ET | 8900 | 1.28 |
| 10:02 ET | 4100 | 1.275 |
| 10:04 ET | 5795 | 1.275 |
| 10:06 ET | 495 | 1.275 |
| 10:08 ET | 1000 | 1.275 |
| 10:09 ET | 6305 | 1.26 |
| 10:11 ET | 14600 | 1.27 |
| 10:13 ET | 4560 | 1.275 |
| 10:15 ET | 6613 | 1.275 |
| 10:18 ET | 5652 | 1.265 |
| 10:20 ET | 4942 | 1.26 |
| 10:22 ET | 5679 | 1.26 |
| 10:24 ET | 2701 | 1.26 |
| 10:26 ET | 1100 | 1.26 |
| 10:27 ET | 37546 | 1.2417 |
| 10:29 ET | 34039 | 1.2305 |
| 10:31 ET | 12911 | 1.24 |
| 10:33 ET | 64714 | 1.2109 |
| 10:36 ET | 50939 | 1.235 |
| 10:38 ET | 5860 | 1.24 |
| 10:40 ET | 34454 | 1.2239 |
| 10:42 ET | 10830 | 1.2161 |
| 10:44 ET | 35038 | 1.23 |
| 10:45 ET | 6540 | 1.2295 |
| 10:47 ET | 24597 | 1.235 |
| 10:49 ET | 5700 | 1.235 |
| 10:51 ET | 13200 | 1.23 |
| 10:54 ET | 22890 | 1.235 |
| 10:56 ET | 8868 | 1.235 |
| 10:58 ET | 165683 | 1.245 |
| 11:00 ET | 66078 | 1.245 |
| 11:02 ET | 11387 | 1.245 |
| 11:03 ET | 17673 | 1.26 |
| 11:07 ET | 200 | 1.25 |
| 11:09 ET | 2100 | 1.25 |
| 11:12 ET | 10071 | 1.255 |
| 11:14 ET | 13107 | 1.255 |
| 11:16 ET | 100 | 1.255 |
| 11:18 ET | 12846 | 1.25 |
| 11:20 ET | 10380 | 1.2497 |
| 11:21 ET | 5157 | 1.2486 |
| 11:23 ET | 2800 | 1.25 |
| 11:25 ET | 7800 | 1.25 |
| 11:27 ET | 14212 | 1.2588 |
| 11:30 ET | 100 | 1.26 |
| 11:32 ET | 100 | 1.26 |
| 11:36 ET | 10696 | 1.255 |
| 11:38 ET | 20426 | 1.25 |
| 11:39 ET | 202 | 1.255 |
| 11:41 ET | 300 | 1.255 |
| 11:43 ET | 100 | 1.255 |
| 11:45 ET | 454 | 1.255 |
| 11:48 ET | 40564 | 1.25 |
| 11:50 ET | 9804 | 1.255 |
| 11:52 ET | 1947 | 1.26 |
| 11:54 ET | 2927 | 1.255 |
| 11:56 ET | 2400 | 1.255 |
| 11:57 ET | 1100 | 1.26 |
| 11:59 ET | 9820 | 1.25 |
| 12:01 ET | 2845 | 1.25 |
| 12:03 ET | 700 | 1.2599 |
| 12:06 ET | 100 | 1.26 |
| 12:08 ET | 10165 | 1.255 |
| 12:10 ET | 100 | 1.255 |
| 12:12 ET | 562 | 1.251 |
| 12:14 ET | 500 | 1.255 |
| 12:15 ET | 23200 | 1.2599 |
| 12:17 ET | 17197 | 1.25 |
| 12:19 ET | 30823 | 1.25 |
| 12:21 ET | 6822 | 1.25 |
| 12:24 ET | 1770 | 1.25 |
| 12:26 ET | 100 | 1.255 |
| 12:28 ET | 34551 | 1.2488 |
| 12:30 ET | 1330 | 1.25 |
| 12:32 ET | 2310 | 1.245 |
| 12:33 ET | 10590 | 1.25 |
| 12:35 ET | 1418 | 1.245 |
| 12:37 ET | 29100 | 1.245 |
| 12:39 ET | 663 | 1.245 |
| 12:42 ET | 750 | 1.25 |
| 12:44 ET | 42581 | 1.255 |
| 12:48 ET | 349 | 1.2513 |
| 12:50 ET | 906 | 1.255 |
| 12:51 ET | 35407 | 1.245 |
| 12:53 ET | 1593 | 1.245 |
| 12:55 ET | 5342 | 1.25 |
| 12:57 ET | 33997 | 1.225 |
| 01:00 ET | 276813 | 1.22 |
Nov 27, 2024
Coherus Management to Participate in the 2024 Citi Global Healthcare Conference, from 4:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 27, 2024 by Dow Jones
Nov 8, 2024
DJ Coherus BioSciences Is Maintained at Outperform by Baird, from 7:38AM ET on Friday Nov 08, 2024 by Dow Jones
7:38AM ET on Friday Nov 08, 2024 by Dow Jones
Nov 7, 2024
DJ Coherus BioSciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 6:34AM ET on Thursday Nov 07, 2024 by Dow Jones
6:34AM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 6, 2024
*DJ Coherus BioSciences 3Q Loss/Shr 9c >CHRS, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 06, 2024 by Dow JonesCoherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Coherus BioSciences Inc | 145.2M | -13.7x | --- |
Voyager Therapeutics Inc | 309.7M | 11.7x | --- |
Ginkgo Bioworks Holdings Inc | 450.0M | -0.7x | --- |
Amarin Corporation PLC | 202.4M | -5.3x | --- |
Revance Therapeutics Inc | 396.5M | -1.9x | --- |
Vanda Pharmaceuticals Inc | 302.6M | -18.2x | -37.98% |
Company Information
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.
Contact Information
- Headquarters
- C/O DENNIS M. LANFEAR 201 REDWOOD SHORES PARKWAY, SUITE 200REDWOOD CITY, CA, United States 94065
- Phone
- 650-649-3530
- Fax
- 302-655-5049
Executives
- Chairman of the Board, President, Chief Executive Officer
- Dennis Lanfear
- Chief Financial Officer
- Bryan Mcmichael
- Chief Development Officer
- Theresa Lavallee
- Chief Commercial Officer
- Paul Reider
- Lead Independent Director
- Mats Wahlstrom
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $145.2M |
|---|---|
Revenue (TTM) | $304.3M |
Shares Outstanding | 115.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.86 |
EPS | $-0.09 |
Book Value | $-1.72 |
P/E Ratio | -13.7x |
Price/Sales (TTM) | 0.5 |
Price/Cash Flow (TTM) | 29.9x |
Operating Margin | 8.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
